These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 16785428)

  • 1. Phosphoproteomic analysis of Her2/neu signaling and inhibition.
    Bose R; Molina H; Patterson AS; Bitok JK; Periaswamy B; Bader JS; Pandey A; Cole PA
    Proc Natl Acad Sci U S A; 2006 Jun; 103(26):9773-8. PubMed ID: 16785428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
    Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phosphoproteomic analysis of the ErbB2 receptor tyrosine kinase signaling pathways.
    Mukherji M; Brill LM; Ficarro SB; Hampton GM; Schultz PG
    Biochemistry; 2006 Dec; 45(51):15529-40. PubMed ID: 17176074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition.
    Rexer BN; Ham AJ; Rinehart C; Hill S; Granja-Ingram Nde M; González-Angulo AM; Mills GB; Dave B; Chang JC; Liebler DC; Arteaga CL
    Oncogene; 2011 Oct; 30(40):4163-74. PubMed ID: 21499296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Houttuyninum, an active constituent of Chinese herbal medicine, inhibits phosphorylation of HER2/neu receptor tyrosine kinase and the tumor growth of HER2/neu-overexpressing cancer cells.
    Zhou NN; Tang J; Chen WD; Feng GK; Xie BF; Liu ZC; Yang D; Zhu XF
    Life Sci; 2012 May; 90(19-20):770-5. PubMed ID: 22525372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu.
    Piechocki MP; Yoo GH; Dibbley SK; Lonardo F
    Cancer Res; 2007 Jul; 67(14):6825-43. PubMed ID: 17638894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.
    Moasser MM; Basso A; Averbuch SD; Rosen N
    Cancer Res; 2001 Oct; 61(19):7184-8. PubMed ID: 11585753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ensemble clustering of phosphoproteomic data identifies differences in protein interactions and cell-cell junction integrity of HER2-overexpressing cells.
    Schaberg KE; Shirure VS; Worley EA; George SC; Naegle KM
    Integr Biol (Camb); 2017 Jun; 9(6):539-547. PubMed ID: 28492659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Global phosphoproteomic effects of natural tyrosine kinase inhibitor, genistein, on signaling pathways.
    Yan GR; Xiao CL; He GW; Yin XF; Chen NP; Cao Y; He QY
    Proteomics; 2010 Mar; 10(5):976-86. PubMed ID: 20049867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of radiosensitivity by dual inhibition of the HER family with ZD1839 ("Iressa") and trastuzumab ("Herceptin").
    Fukutome M; Maebayashi K; Nasu S; Seki K; Mitsuhashi N
    Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):528-36. PubMed ID: 16965995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of type I growth factor receptor tyrosine kinase inhibitors on phosphorylation and transactivation activity of the androgen receptor in prostate cancer cells: Ligand-independent activation of the N-terminal domain of the androgen receptor.
    Sugita S; Kawashima H; Tanaka T; Kurisu T; Sugimura K; Nakatani T
    Oncol Rep; 2004 Jun; 11(6):1273-9. PubMed ID: 15138566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphorylation of mutationally introduced tyrosine in the activation loop of HER2 confers gain-of-function activity.
    Hu Z; Wan X; Hao R; Zhang H; Li L; Li L; Xie Q; Wang P; Gao Y; Chen S; Wei M; Luan Z; Zhang A; Huang N; Chen L
    PLoS One; 2015; 10(4):e0123623. PubMed ID: 25853726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erlotinib directly inhibits HER2 kinase activation and downstream signaling events in intact cells lacking epidermal growth factor receptor expression.
    Schaefer G; Shao L; Totpal K; Akita RW
    Cancer Res; 2007 Feb; 67(3):1228-38. PubMed ID: 17283159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
    Hirata A; Hosoi F; Miyagawa M; Ueda S; Naito S; Fujii T; Kuwano M; Ono M
    Cancer Res; 2005 May; 65(10):4253-60. PubMed ID: 15899817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
    Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
    Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner.
    Bos M; Mendelsohn J; Kim YM; Albanell J; Fry DW; Baselga J
    Clin Cancer Res; 1997 Nov; 3(11):2099-106. PubMed ID: 9815602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells.
    Huang Y; Li X; Jiang J; Frank SJ
    Oncogene; 2006 Dec; 25(58):7565-76. PubMed ID: 16785991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling HER2 effects on cell behavior from mass spectrometry phosphotyrosine data.
    Kumar N; Wolf-Yadlin A; White FM; Lauffenburger DA
    PLoS Comput Biol; 2007 Jan; 3(1):e4. PubMed ID: 17206861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.
    Gilmer TM; Cable L; Alligood K; Rusnak D; Spehar G; Gallagher KT; Woldu E; Carter HL; Truesdale AT; Shewchuk L; Wood ER
    Cancer Res; 2008 Jan; 68(2):571-9. PubMed ID: 18199554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.
    Scaltriti M; Rojo F; Ocaña A; Anido J; Guzman M; Cortes J; Di Cosimo S; Matias-Guiu X; Ramon y Cajal S; Arribas J; Baselga J
    J Natl Cancer Inst; 2007 Apr; 99(8):628-38. PubMed ID: 17440164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.